On Thursday, BofA Securities adjusted its stance on Privia Health Group Inc (NASDAQ:PRVA), downgrading the stock from Buy to Neutral and reducing the price target to $21 from $27. The revision comes as the firm reevaluates the expected EBITDA growth for the healthcare company.
The downgrade was prompted by a reassessment of Privia Health's long-term EBITDA growth potential. BofA Securities now anticipates a 20% increase in EBITDA for 2023, a revision from the previously forecasted 30%-40% growth. This expectation adjustment is primarily due to the performance of the company's value-based care (VBC) segment, which has not met initial expectations.
According to the BofA Securities analyst, the underperformance is largely attributed to delays in the VBC segment, which are expected to last an additional one to two years because of utilization and coding pressures. This setback has prompted the firm to revise its projections and price objective for Privia Health.
The new price objective of $21 is based on a multiple of 23 times the firm's revised 2025 EBITDA estimate for Privia Health. This estimate now falls below the consensus, signaling a more conservative outlook on the company's financial trajectory.
Privia Health's stock rating and price target changes reflect BofA Securities' updated expectations for the company's near-term performance and growth outlook. The revised price target is a direct result of the recalibrated EBITDA growth forecast and the observed challenges within Privia Health's VBC operations.
InvestingPro Insights
In light of BofA Securities' downgrade of Privia Health Group Inc (NASDAQ:PRVA), it's worth considering additional financial metrics and analyst insights that could provide a broader perspective on the company's current valuation and future prospects.
InvestingPro data shows that Privia Health has a market capitalization of $2.33 billion USD. The company's P/E ratio, as of the last twelve months leading up to Q3 2023, stands at 61.89, which might suggest a premium valuation compared to the market average. However, the PEG ratio, which measures a stock's price-to-earnings relative to its earnings growth rate, is at 0.34—indicating that the stock could be undervalued if the company meets growth expectations.
Revenue growth remains robust, with a 24.75% increase over the last twelve months as of Q3 2023. This is complemented by a gross profit margin of 10.07%, although this figure could raise concerns about the company's profitability when compared to industry peers. Operating income margin at 1.36% further underscores the challenges in translating top-line growth to the bottom line.
From the collection of InvestingPro Tips, two stand out as particularly relevant given the context of the BofA Securities report:
1. Analysts predict the company will be profitable this year, which aligns with BofA Securities' assessment of EBITDA growth, albeit at a revised rate.
2. Privia Health is trading near its 52-week low, suggesting that the market may have already priced in some of the challenges faced by the company's VBC segment.
For investors seeking a comprehensive analysis, there are additional InvestingPro Tips available, offering in-depth insights into Privia Health's financial health and market position. With the special coupon code PRONEWS24, readers can get an extra 10% off a yearly or biyearly Pro and Pro+ subscription, gaining access to all the valuable tips that can guide investment decisions. Currently, there are 11 more tips listed on InvestingPro that could be beneficial for those evaluating Privia Health's stock.
The InvestingPro Fair Value estimate of $22.37 USD also provides a point of comparison against BofA Securities' revised price target, as well as the analyst consensus target of $30.5 USD. This discrepancy highlights the diverse opinions on the company's valuation and the importance of conducting thorough research before making investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.